drugset
drugset / Trial / NCT04373603

Use of Tranexamic Acid in Facial Fillers

NCT04373603 ↗

Phase 4 Withdrawn University of Wisconsin, Madison
RandomizedSingle-groupDouble-blindSupportive care

Summary

The overall purpose of this study is to evaluate the safety and efficacy of co-administration of tranexamic acid (TXA) with hyaluronic acid (HA) in reducing swelling, bruising and pain after facial injection. This will be done by comparing HA to HA+TXA in participants undergoing facial filler injections. Patients undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Swelling, bruising, pain, and overall satisfaction will be assessed using participant self-reported surveys, physician surveys, and review of medical records.

Timeline

Start
2022-07
Primary completion
2023-07
Completion
2023-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 0.2 ml Other
Background Hyaluronic Acid Other / unclassified 1 ml Other

Indications

No indication recorded.